MOGS抗体;MOGS Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer using P13455(MOGS Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil using P13455(MOGS Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

MOGS (mannosyl-oligosaccharide glucosidase), also known as glucosidase I, is an endoplasmic reticulum-resident enzyme critical for N-glycosylation, a process essential for protein folding and quality control. It catalyzes the removal of terminal glucose residues from nascent glycoproteins, a key step in the calnexin/calreticulin chaperone cycle. Mutations in the *MOGS* gene cause congenital disorder of glycosylation type IIb (CDG-IIb), a rare autosomal recessive disease characterized by severe neurodevelopmental defects, immunodeficiency, and skeletal abnormalities.

Anti-MOGS antibodies, though less studied compared to other autoimmune targets, have been implicated in rare autoimmune or paraneoplastic conditions. These antibodies may disrupt glycoprotein processing, potentially contributing to cellular dysfunction. However, their clinical significance remains unclear due to limited reported cases. Research primarily focuses on genetic *MOGS* defects rather than acquired antibody-mediated pathologies. In contrast, myelin oligodendrocyte glycoprotein (MOG)-specific antibodies are well-established biomarkers in demyelinating disorders like MOG antibody-associated disease (MOGAD), highlighting the distinction between MOGS (enzyme) and MOG (myelin protein). Further studies are needed to elucidate the role of MOGS antibodies in human diseases.

(Word count: 199)